Insider Selling: OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Sells $403,262.00 in Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Squadron Capital Llc sold 16,300 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $24.74, for a total transaction of $403,262.00. Following the sale, the insider directly owned 6,881,464 shares in the company, valued at $170,247,419.36. This trade represents a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Wednesday, August 26th, Squadron Capital Llc sold 18,000 shares of OrthoPediatrics stock. The shares were sold at an average price of $24.28, for a total transaction of $437,040.00.
• On Monday, August 24th, Squadron Capital Llc sold 4,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $25.75, for a total transaction of $103,000.00.

OrthoPediatrics Stock Up 1.4%

Shares of KIDS stock opened at $23.65 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78. The firm’s 50-day moving average is $21.41 and its 200-day moving average is $18.66. The stock has a market cap of $617.50 million, a price-to-earnings ratio of -14.08 and a beta of 0.98. OrthoPediatrics Corp. has a 52-week low of $14.42 and a 52-week high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Sell-side analysts predict that OrthoPediatrics Corp. will post -1.14 EPS for the current year.

Institutional Investors Weigh In On OrthoPediatrics

Institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. grew its stake in shares of OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after acquiring an additional 1,139 shares in the last quarter. Legal & General Group Plc acquired a new stake in OrthoPediatrics in the 2nd quarter worth about $34,000. Northwestern Mutual Wealth Management Co. raised its stake in OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after purchasing an additional 2,561 shares in the last quarter. Caption Management LLC bought a new stake in OrthoPediatrics in the 3rd quarter valued at about $54,000. Finally, BNP Paribas Financial Markets boosted its holdings in OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after purchasing an additional 1,235 shares during the period. Institutional investors own 69.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Piper Sandler reissued an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Needham & Company LLC upped their price objective on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. BTIG Research raised their target price on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Finally, TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, OrthoPediatrics currently has an average rating of “Moderate Buy” and an average price target of $26.44.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.